Market Overview:
Antisense oligonucleotides are short single-stranded DNA or RNA molecules that are designed to specifically bind to target messenger RNA (mRNA) transcripts and regulate gene expression by inhibiting translation or triggering degradation of mRNA. They have potential applications in treating genetic disorders, cancer, and viral infections among others. Rapid advancements in oligonucleotide chemistry and non-clinical research have enabled the development of third-generation Antisense Oligonucleotides with improved pharmacological properties and significantly higher target affinity.
Market key trends:
The antisense oligonucleotides market is witnessing significant growth due to rising research activities by pharmaceutical companies. According to Pharmaceutical Research and Manufacturers of America (PhRMA), member biopharmaceutical companies invested an estimated US$ 83 billion in research and development in 2020, which increased by over 30% from 2012 spending levels. Moreover, nucleic acid-based drugs has gained immense popularity over the past decade due to their high target specificity and fewer side effects compared to conventional drugs. This coupled with successful commercialization of antisense drugs such as nusinersen by Biogen and inclisiran by Novartis/Alnylam have created enormous opportunity for novel antisense oligonucleotides to enter the market in the near future.
The global Antisense Oligonucleotides Market Share is estimated to be valued at US$ 2,913.5 Mn in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Porter’s Analysis
Threat of new entrants: The high R&D costs and regulatory barriers pose a threat of low new entrants in the Antisense Oligonucleotides market.
Bargaining power of buyers: The large pharmaceutical companies have significant bargaining power of buyers over smaller biotechnology companies in the market.
Bargaining power of suppliers: The sophisticated manufacturing techniques require dependence on few specialized suppliers giving them bargaining power over biotech companies.
Threat of new substitutes: The new substitute products for treating genetic disorders can pose a threat to the existing Antisense Oligonucleotides products.
Competitive rivalry: Intense competition exists among the established key players to develop advanced therapeutics.
Key Takeaways
The global Antisense Oligonucleotides market is expected to witness high growth, exhibiting CAGR of 6.6% over the forecast period, due to increasing demand for novel biotechnologies in genetic disorder treatment.
Regional analysis: North America dominates the global Antisense Oligonucleotides market currently. However, Asia Pacific region is expected to exhibit fastest growth over the forecast period due to increasing R&D investments by government and private companies in the development of precision medicines for genetic disorders.
Key players: Key players operating in the Antisense Oligonucleotides market are Antisense Therapeutics, Biogen, Bio-Path Holdings, Ionis Pharmaceuticals, ProQR Therapeutics, Sarepta Therapeutics, Sterna Biologicals and Wave Life Sciences.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
